Ardent Health Partners Inc. Reports 4% Increase in Sales and 52% Rise in Net Income for Q1 2025; EPS Climbs to $0.29

Reuters
05-07
Ardent Health Partners Inc. Reports 4% Increase in Sales and 52% Rise in Net Income for Q1 2025; EPS Climbs to $0.29

Ardent Health Partners Inc. has announced its financial results for the first quarter of 2025, reporting a total revenue of $1.50 billion, marking a 4.0% growth compared to the same period in the previous year. The company's net income attributable to Ardent Health reached $41 million, translating to $0.29 per diluted share, showing an increase from $27 million, or $0.21 per diluted share, in the first quarter of 2024. Adjusted EBITDA experienced a 2.5% increase year-over-year, reaching $98 million. In terms of admissions, Ardent Health reported a 7.6% growth year-over-year, totaling 41,389 admissions, while adjusted admissions rose by 2.7% to 84,536. However, outpatient surgeries saw a slight decline of 2.3%. The company has reaffirmed its full-year 2025 financial guidance, projecting total revenue between $6.2 billion and $6.45 billion and net income attributable to Ardent Health between $245 million and $285 million. Adjusted EBITDA is expected to be in the range of $575 million to $615 million. The company's guidance also anticipates adjusted admissions growth between 2.0% and 3.0%. Ardent Health continues to focus on operational excellence, achieving a reduction in supply costs and moderating the growth of professional fee expenses. The company is exploring inorganic growth opportunities, leveraging its strong balance sheet to pursue value-enhancing transactions and expressing interest in its joint venture model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardent Health Partners Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250506435525) on May 06, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10